Energy shares lead broad rebound on Wall Street
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Francesca\'s Holdings (FRAN) PT Lowered to $8 at FBR Capital Following 2Q
September 6, 2017 1:40 PM EDTFBR Capital lowered its price target on Francesca\'s Holdings (NASDAQ: FRAN) to $8.00 (from $10.00) while maintaining a Neutral rating following the company's 2Q earnings release. FRAN reported EPS of $0.20, versus the consensus estimate of $0.19. Management guided 3Q17 well below the Street due to... More
Sarepta (SRPT) Could See Exon 53 Approval in 2018, Peak Sales of ~$800M - William Blair
September 6, 2017 11:06 AM EDTWilliam Blair analyst Tim Lugo weighed in on Sarepta Therapeutics (NASDAQ: SRPT) after the company announced positive interim 48-week data from its ongoing European Phase I/II study for DMD patients amenable to skipping exon 53 with golodirsen (SRP-4053).
Lugo notes all... More
UPDATE: Sarepta Therapeutics (SRPT) PT Raised to $55 at Piper Jaffray
September 6, 2017 10:57 AM EDT(Updated - September 6, 2017 11:00 AM EDT)
(updated to add analyst comment)
Piper Jaffray raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $55.00 (from $50.00) while maintaining a Overweight rating.
Analyst Edward Tenthoff notes the positive Exon 53 data. The analyst further comments... More
HP Enterprise (HPE) PT Lowered to $14 at Susquehanna Following 3Q
September 6, 2017 8:10 AM EDTSusquehanna lowered its price target on HP Enterprise (NYSE: HPE) to $14.00 (from $17.00) while maintaining a Neutral rating following the company's 3Q earnings report. HPE delivered Jul Q revenues and EPS of $8.2B and $0.30 vs. the consensus of $7.5B/$0.26.
HPE's Oct Q guidance of $0.28 is below... More
